La radio-immunothérapie dans les cancers ovariens

  • F. Giammarile
  • T. Mognetti
Part of the Abord clinique book series (ONCOLPRAT)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kairemo KJ (1996) Radioimmunotherapy of solid cancers: A review. Acta Oncol. 35(3): 343–55PubMedGoogle Scholar
  2. 2.
    Wong JYC, Chu DZ, Yamauchi DM et al. (2000) A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res. 6(10): 3855–63PubMedGoogle Scholar
  3. 3.
    Rosenblum MG, Verschraegen CF, Murray JL et al. (1999) Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res. 5(5): 953–61PubMedGoogle Scholar
  4. 4.
    Alvarez RD, Huh WK, Khazaeli MB et al. (2002) A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res. 8(9): 2806–11PubMedGoogle Scholar
  5. 5.
    Janssen ML, Pels W, Massuger LF et al. (2003) Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: Effect of the radionuclide. Int J Gynecol Cancer 13(5): 607–13CrossRefPubMedGoogle Scholar
  6. 6.
    van Zanten-Przybysz I, Molthoff CF, Roos JC et al. (2001) Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18:i.v. vs. i.p. Int J Cancer 92(1): 106–14PubMedGoogle Scholar
  7. 7.
    Buchsbaum DJ, Rogers BE, Khazaeli MB et al. (1990) Targeting strategies for cancer radiotherapy. Clin Cancer Res. 5(10 Suppl): 3048s–3055sGoogle Scholar
  8. 8.
    Grana C, Bartolomei M, Handkiewicz D et al. (2004) Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin? Gynecol Oncol 93(3): 691–8CrossRefPubMedGoogle Scholar
  9. 9.
    Meredith RF, Alvarez RD, Partridge EE et al. (2001) Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm. 16(4): 305–15CrossRefPubMedGoogle Scholar
  10. 10.
    Epenetos AA, Hird V, Lambert H et al. (2000) Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 10(S1): 44–6CrossRefPubMedGoogle Scholar
  11. 11.
    Mahe MA, Fumoleau P, Fabbro M et al. (1999) A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res 5(10 Suppl): 3249s–3253sPubMedGoogle Scholar
  12. 12.
    Juweid M, Swayne LC, Sharkey RM et al. (1997) Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies. Gynecol Oncol 67(3): 259–71CrossRefPubMedGoogle Scholar
  13. 13.
    Alvarez RD, Partridge EE, Khazaeli MB et al. (1997) Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 65(1): 94–101CrossRefPubMedGoogle Scholar
  14. 14.
    Crippa F, Bolis G, Seregni E et al. (1995) Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 31A(5): 686–90PubMedGoogle Scholar
  15. 15.
    Jacobs AJ, Fer M, Su FM et al. (1993) A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obstet Gynecol 82(4 Pt 1): 586–93PubMedGoogle Scholar
  16. 16.
    Muto MG, Finkler NJ, Kassis AI et al. (1992) Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. Gynecol Oncol 45(3): 265–72CrossRefPubMedGoogle Scholar
  17. 17.
    Stewart JS, Hird V, Snook D et al. (1990) Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 8(12): 1941–50PubMedGoogle Scholar
  18. 18.
    Finkler NJ, Muto MG, Kassis AI et al. (1989) Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer. Gynecol Oncol 34(3): 339–44CrossRefPubMedGoogle Scholar
  19. 19.
    Stewart JS, Hird V, Sullivan M et al. (1989) Intraperitoneal radioimmuno-therapy for ovarian cancer. Br J Obstet Gynaecol 96(5): 529–36PubMedGoogle Scholar
  20. 20.
    Stewart JS, Hird V, Snook D et al. (1989) Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys 16(2): 405–13PubMedGoogle Scholar
  21. 21.
    Riva P, Marangolo M, Lazzari S et al. (1989) Locoregional immunotherapy of human ovarian cancer: preliminary results. Int J Rad Appl Instrum B 16(6): 659–66PubMedGoogle Scholar
  22. 22.
    Leichner PK, Rosenshein NB, Leibel SA et al. (1980) Distribution and tissue dose of intraperitoneally administered radioactive chromic phosphate (32P) in New Zealand white rabbits. Radiology 134(3): 729–34PubMedGoogle Scholar
  23. 23.
    Epenetos AA, Munro AJ, Stewart S et al. (1987) Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 5(12): 1890–9PubMedGoogle Scholar
  24. 24.
    Stewart JS, Hird V, Snook D et al. (1988) Intraperitoneal 131I-and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Int J Cancer Suppl 3: 71–6PubMedGoogle Scholar
  25. 25.
    Meredith RF, Partridge EE, Alvarez RD et al. (1996) Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med 37(9): 1491–6PubMedGoogle Scholar
  26. 26.
    Horak E, Hartmann F, Garmestani K et al. (1997) Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med 38(12): 1944–50PubMedGoogle Scholar
  27. 27.
    Andersson H, Lindegren S, Back T et al. (2000) Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18. Anticancer Res 20(1A): 459–62PubMedGoogle Scholar
  28. 28.
    Andersson H, Lindegren S, Back T et al. (2000) The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts—a long-term study. Acta Oncol 39(6): 741–5PubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • F. Giammarile
  • T. Mognetti

There are no affiliations available

Personalised recommendations